All In Biotech

Drug Trial Radar · NCT06463587

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

264

Planned (sponsor's estimate)

Start

Jun 25, 2024

Primary completion

Aug 23, 2028

Study completion Nov 12, 2030

Sponsor

Sponsor type
Industry
Collaborators
EMD Serono Research & Development Institute, Inc.
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of oral cladribine in gMG. An additional component is included to characterize the Pharmacokinetics (PK) of the new cladribine formulation in gMG participants. This study is divided into 3 periods: the double-blind placebo control (DBPC) pivotal period, and 2 extensions, the blinded extension (BE) and the retreatment (RT) period. Furthermore, in trial interviews will be conducted as a sub-study to MyClad with a sub-set of participants to gain an in depth understanding of the participant cladribine treatment and study experience.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • PlaceboOther

    Participants will receive placebo matched to cladribine in two courses separated by 4 weeks.

  • Cladribine Low DoseDrug

    Participants will receive cladribine low dose in two courses separated by 4 weeks.

  • Cladribine High DoseDrug

    Participants will receive cladribine high dose in two courses separated by 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) PeriodTime frame: Baseline, Week 24

Locations

159 sites in 26 countries. Site status is shown where the registry gives one.

  • Arizona Neuroscience Research, LLC

    Phoenix, Arizona · Recruiting

  • Advanced Neurosciences Research LLC

    Longmont, Colorado · Active not recruiting

  • University of Connecticut Health Center - Department of Medicine

    Farmington, Connecticut · Recruiting

  • The George Washington University Medical Faculty Associates Foggy Bottom South Pavilion

    Washington D.C., District of Columbia · Recruiting

  • Neurology of Central Florida Research Center, LLC

    Altamonte Springs, Florida · Recruiting

  • SFM Clinical Research, LLC

    Boca Raton, Florida · Recruiting

  • University of Florida Health Science Center - 300120311

    Jacksonville, Florida · Recruiting

  • Neurology Associates, P. A.

    Maitland, Florida · Recruiting

  • University of South Florida - PARENT - PARENT

    Tampa, Florida · Recruiting

  • University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN)

    Kansas City, Kansas · Recruiting

  • UNC Hospitals - PARENT

    Chapel Hill, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina · Recruiting

  • Miami Valley Hospital South

    Centerville, Ohio · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • Clinical Trials of South Carolina - Charleston

    Charleston, South Carolina · Recruiting

  • Erlanger Health, Inc. - 1123255

    Chattanooga, Tennessee · Recruiting

  • Baylor Scott & White Research Institute - Baylor Scott & White Research Institute

    Dallas, Texas · Recruiting

  • ANESC Research

    El Paso, Texas · Recruiting

  • DHR Health Institute for Research and Development

    McAllen, Texas · Recruiting

  • Baylor Scott & White Neurology - McKinney

    McKinney, Texas · Recruiting

  • The University of Vermont Medical Center

    Burlington, Vermont · Recruiting

  • Integrated Neurology Services - Dr. Simon Fishman's Office

    Falls Church, Virginia · Active not recruiting

  • BCN Research

    Greenfield, Wisconsin · Recruiting

  • Expertia S.A- Mautalen Salud e Investigación

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Neurologicas Raul Carrea, FLENI - de Investigaciones Clinicas del área de Cardiología y enfermedades metabólicas asociadas

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Metabolicas (IDIM)

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Hospital Cordoba

    Córdoba, Argentina · Recruiting

  • Fundacion Rosarina de Neurorehabilitacion

    Rosario, Argentina · Recruiting

  • INECO Neurociencias Oroño

    Rosario, Argentina · Recruiting

  • CER San Juan Centro Polivalente de Asistencia e Inv. Clinica

    San Juan, Argentina · Recruiting

  • Centro de Investigaciones Medicas Tucuman

    San Miguel de Tucumán, Argentina · Recruiting

  • Gold Coast University Hospital - PARENT

    Southport, Australia · Recruiting

  • Brain and Mind Research Institute

    Camperdown, New South Wales, Australia · Recruiting

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia · Recruiting

  • Princess Alexandra Hospital - PARENT

    South Brisbane, Queensland, Australia · Recruiting

  • John Hunter Hospital - PARENT

    City of Burnside, South Australia, Australia · Recruiting

  • Box Hill Hospital - PARENT

    Box Hill, Victoria, Australia · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • C. H. R. de la Citadelle - Account 1

    Liège, Belgium · Recruiting

  • Medical Center Hera - branch Montana

    Montana, Bulgaria · Recruiting

Showing 40 of 159 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.